Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?
NNRTIs and protease inhibitors both good for first ART, channelling affects choices
South African women living with HIV subtype C experience rapid CD4 cell loss
Efavirenz use not linked to neurocognitive impairment
Dolutegravir demonstrates good efficacy despite resistance
Could HIV treatment mean safer sex?
Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment
